Clinical Trials Browser

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT05770102 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

DermatologicGastrointestinalGynecologicLymphoid

Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Colorectal Neoplasms, Endometrial Neoplasms

NCT05770544 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

CNSDermatologicLymphoidOther hematologic neoplasm

Brain Neoplasms, Glioma, Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT01861938 2025-10-02

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

Phase 2/3 Withdrawn

Dermatologic

Melanoma, Neoplasm Metastasis

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 2 FDA

Dermatologic

Melanoma, Neoplasms

NCT04695977 2025-09-05

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Phase 2/3 Terminated

20 enrolled 18 charts

Dermatologic

Melanoma

Clinical Trials

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

INTerpath-007

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Contrast-enhanced Ultrasound for Sentinel Node Detection

DETERMINE

DETERMINE

DETERMINE

DETERMINE

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

RELATIVITY-047

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma